Vascular outcome in type 2 diabetes: an ADVANCE?

Lancet

Volumn 370, Issue 9590, 2007, Pages 804-805

  Kaplan, Norman M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; LISINOPRIL; PERINDOPRIL; PLACEBO; POLYPILL; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; BLOOD PRESSURE REGULATION; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; FOLLOW UP; HUMAN; HYPERTENSION; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK REDUCTION; VALIDATION PROCESS; VASCULAR DISEASE;

EID: 34548392359     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61304-X     Document Type: Note

References (5)

1. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet (2007). published online Sept 2, 2007. DOI:10.1016/S0140-6736(07)61303-8
2. Kaplan N. Treatment of hypertension: drug therapy. Kaplan's clinical hypertension. 9th edn. (2006), Lippincott Williams and Wilkins, Philadelphia 257-258
3. Kaplan N. Treatment of hypertension: drug therapy. Kaplan's clinical hypertension. 9th edn. (2006), Lippincott Williams and Wilkins, Philadelphia 264-265
4. Wald N., and Law M. A strategy to reduce cardiovascular disease by more than 80%. BMJ 326 (2003) 1419-1423
5. Staessen J., Wang J.-G., and Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 21 (2003) 1055-1076